New drug combo aims to boost leukemia remission

NCT ID NCT01627041

First seen Oct 31, 2025 · Last updated Jun 13, 2026 · Updated 36 times

Summary

This study tests whether adding the drug decitabine to standard chemotherapy can help more adults with acute myeloid leukemia (AML) achieve remission. About 178 participants will receive either low or high doses of decitabine alongside chemo drugs. The goal is to see if this approach improves the chance of cancer disappearing after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Case Western Reserve University

    Cleveland, Ohio, 44106, United States

  • Lafayette Family Cancer Center-EMMC

    Brewer, Maine, 04412, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Montefiore Medical Center - Moses Campus

    The Bronx, New York, 10467, United States

  • Montefiore Medical Center-Weiler Hospital

    The Bronx, New York, 10461, United States

  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

    New York, New York, 10032, United States

  • NYP/Weill Cornell Medical Center

    New York, New York, 10065, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

Conditions

Explore the condition pages connected to this study.